GlassScriptPhysician profile
Jonathan I Orwitz
NPI 1659486611
$3,667.42
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,542 · 2020: $253 · 2021: $1,166 · 2022: $707.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $559.91 | 2019-2021 | |
| Biogen, INC. | $445.91 | 2019-2022 | |
| Ucb, INC. | $259.97 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $230.79 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $162.23 | 2019-2020 | |
| Abbvie INC. | $135.45 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $120.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $117.75 | 2019-2021 | |
| Emd Serono, INC. | $116.93 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $109.38 | 2019-2022 | |
| Lilly USA, LLC | $109.17 | 2019 | |
| Genentech USA, INC. | $95.11 | 2019-2020 | |
| Kyowa Kirin, INC. | $82.23 | 2020-2022 | |
| Adamas Pharmaceuticals, INC. | $72.44 | 2019-2021 | |
| Genzyme Corporation | $72.38 | 2019-2022 |
Show all 42 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Orwitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.